Literature DB >> 9062894

Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau.

G Farías1, C González-Billault, R B Maccioni.   

Abstract

The microtubule-associated protein tau is the main structural component of paired helical filaments (PHFs), which in turn are one of the major aberrant polymers found in Alzheimer's disease. Immunological studies were carried out using site-directed monoclonal and polyclonal antibodies that recognize tubulin binding epitopes on tau, to further understand the mechanisms of tau self-association into PHFs. Tau protein was subjected to either carbamoylation with potassium cyanate (KCNO) or glycation with glucose, and the immunoreactivity of the chemically-modified protein with these antibodies was compared with tau derived from paired helical filaments and with normal brain tau. The data on the immunoblot patterns of tau isoforms and the ELISA titration curves revealed significant differences between the modified tau and normal controls. However, the Western blot patterns of immunoreactive tau from the chemically-modified protein and from Alzheimer brains were similar. The data on the differences in the electrophoretic profiles and Western blots of normal brain tau as compared with solubilized paired helical filaments, insoluble tangles and tau proteins of the Alzheimer's type, provide new clues to understand the anomalous interactions of tau in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062894     DOI: 10.1023/a:1006838626730

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  46 in total

1.  Carboxyl terminal sequences of beta-tubulin involved in the interaction of HMW-MAPs. Studies using site-specific antibodies.

Authors:  D Cross; G Farías; J Domínguez; J Avila; R B Maccioni
Journal:  Mol Cell Biochem       Date:  1994-03-16       Impact factor: 3.396

2.  Tau-related protein present in paired helical filaments has a decreased tubulin binding capacity as compared with microtubule-associated protein tau.

Authors:  A Nieto; I Correas; C López-Otín; J Avila
Journal:  Biochim Biophys Acta       Date:  1991-04-15

3.  Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome.

Authors:  S Flament; A Delacourte; D M Mann
Journal:  Brain Res       Date:  1990-05-14       Impact factor: 3.252

4.  Immunological characterization of the region of tau protein that is bound to Alzheimer paired helical filaments.

Authors:  C B Caputo; C Wischik; M Novak; C W Scott; W F Brunner; E M De Garcini; M M Lo; T E Norris; A I Salama
Journal:  Neurobiol Aging       Date:  1992 Mar-Apr       Impact factor: 4.673

5.  Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.

Authors:  A Takashima; K Noguchi; K Sato; T Hoshino; K Imahori
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

6.  Analysis of microtubule-associated protein tau glycation in paired helical filaments.

Authors:  M D Ledesma; P Bonay; C Colaço; J Avila
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

Review 7.  Radical AGEing in Alzheimer's disease.

Authors:  M A Smith; L M Sayre; V M Monnier; G Perry
Journal:  Trends Neurosci       Date:  1995-04       Impact factor: 13.837

8.  The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway.

Authors:  T Oltersdorf; P J Ward; T Henriksson; E C Beattie; R Neve; I Lieberburg; L C Fritz
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

9.  Tau protein function in living cells.

Authors:  D G Drubin; M W Kirschner
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

10.  Differential interaction of synthetic peptides from the carboxyl-terminal regulatory domain of tubulin with microtubule-associated proteins.

Authors:  R B Maccioni; C I Rivas; J C Vera
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  6 in total

1.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.

Authors:  Leonel E Rojo; Jans Alzate-Morales; Iván N Saavedra; Peter Davies; Ricardo B Maccioni
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Avenues for post-translational protein modification prevention and therapy.

Authors:  Mengyao Tang; Sahir Kalim
Journal:  Mol Aspects Med       Date:  2022-02-25

Review 3.  Protein carbamylation in end stage renal disease: is there a mortality effect?

Authors:  Sahir Kalim
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-11       Impact factor: 2.894

Review 4.  Protein carbamylation and cardiovascular disease.

Authors:  Frederik H Verbrugge; W H Wilson Tang; Stanley L Hazen
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

5.  Phage-Display-Derived Peptide Specific to Carbamylated Protein.

Authors:  Yuhao Ma; Meng Wu; Shuhui Li; Marcello Tonelli; Larry D Unsworth
Journal:  ACS Omega       Date:  2021-01-25

Review 6.  Protein carbamylation in kidney disease: pathogenesis and clinical implications.

Authors:  Sahir Kalim; S Ananth Karumanchi; Ravi I Thadhani; Anders H Berg
Journal:  Am J Kidney Dis       Date:  2014-07-16       Impact factor: 8.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.